Lixuan Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lixuan Ren has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Suk Kong
Department of Bioscience, Silla University, Busan 46958, Republic of Korea
4 shared publications - Fang Tan
Department of Bioscience, Silla University, Busan 46958, Republic of Korea
3 shared publications Fang Tan
Department of Bioscience, Silla University, Busan, 46958 Republic of Korea
1 shared publicationHyo-Eun Kim
Nutritional Education, Graduate School of Education, Silla University, Busan, 46958 Korea
1 shared publication- Jung Hwan Oh
Nutritional Education, Graduate School of Education, Silla University
1 shared publication - Mi-Geon Jo
Department of Food and Nutrition, Silla University, Busan, Republic of Korea
1 shared publication
Latest Publications
- 17 November 2025
- Published by Springer Nature in Food Science and Biotechnology
- Vol. 35 (1) , 229-237
Immunoregulatory effects of Bifidobacterium animalis subsp. animalis QC08 on cyclophosphamide-induced immunosuppression in mice
This study investigated the immunomodulatory effects of Bifidobacterium animalis subsp. animalis QC08 on cyclophosphamide (CTX)-induced immunosuppression in male Kunming mice, randomly divided into five groups: normal, control, positive control (levamisole hydrochloride, 40 mg/kg), low-dose QC08 (2 × 108 CFU/kg), and high-dose QC08 (2 × 1010 CFU/kg). After 21 days of intervention, assessments revealed that both QC08 groups significantly improved body weight, spleen/thymus indices, and histopathological damage in thymus/spleen compared to the model group. Serum pro-inflammatory cytokines (IL-1, TNF-α, IL-6) decreased while anti-inflammatory IL-4 increased. Quantitative real-time PCR of ileal tissue showed upregulated expression of intestinal barrier genes (claudin-1, ZO-1, JAM-A, MUPP1, IKKα, IKKγ) and downregulated inflammatory signaling genes (p50, p52). These results demonstrate that QC08 effectively ameliorates CTX-induced immunosuppression by modulating immune responses and enhancing intestinal barrier integrity, supporting the potential of B. animalis subsp. animalis QC08 for immune-enhancing health food development.
- 17 November 2025
- Published by Springer Nature in Food Science and Biotechnology
- Vol. 35 (1) , 229-237
Immunoregulatory effects of Bifidobacterium animalis subsp. animalis QC08 on cyclophosphamide-induced immunosuppression in mice
This study investigated the immunomodulatory effects of Bifidobacterium animalis subsp. animalis QC08 on cyclophosphamide (CTX)-induced immunosuppression in male Kunming mice, randomly divided into five groups: normal, control, positive control (levamisole hydrochloride, 40 mg/kg), low-dose QC08 (2 × 108 CFU/kg), and high-dose QC08 (2 × 1010 CFU/kg). After 21 days of intervention, assessments revealed that both QC08 groups significantly improved body weight, spleen/thymus indices, and histopathological damage in thymus/spleen compared to the model group. Serum pro-inflammatory cytokines (IL-1, TNF-α, IL-6) decreased while anti-inflammatory IL-4 increased. Quantitative real-time PCR of ileal tissue showed upregulated expression of intestinal barrier genes (claudin-1, ZO-1, JAM-A, MUPP1, IKKα, IKKγ) and downregulated inflammatory signaling genes (p50, p52). These results demonstrate that QC08 effectively ameliorates CTX-induced immunosuppression by modulating immune responses and enhancing intestinal barrier integrity, supporting the potential of B. animalis subsp. animalis QC08 for immune-enhancing health food development.
- 15 May 2025
- Published by Springer Nature in Food Science and Biotechnology
- Vol. 34 (11) , 2625-2634
The role of Bifidobacterium animalis QC08 in antibiotic-associated diarrhea in mice
Excessive antibiotic use can lead to gut microbiota dysbiosis, resulting in diarrhea. This study aimed to investigate the effects of Bifidobacterium animalis QC08 (QC08) on the antibiotic-induced diarrhea mouse model using lincomycin hydrochloride. Mice were divided into five groups: normal, diarrhea, a drug group, high-dose QC08 (QC08-H), low-dose QC08 (QC08-L). Compared with the diarrhea group, the QC08-H and QC08-L groups showed a decrease in serum serotonin, interleukin (IL)-17A, IL-6, and malondialdehyde levels, whereas total antioxidant capacity levels increased. In the colon and small intestine tissues of QC08-H and QC08-L treated mice, mRNA expression of cystic fibrosis transmembrane conductance regulator (CFTR), epidermal growth factor receptor (EGFR), and transforming growth factor β1 (TGFβ1) was significantly downregulated, whereas expression of sodium-hydrogen exchanger 1 (NHE1) and NHE4 was upregulated compared to the AAD model group. Altogether, this in vivo study demonstrates the potential of QC08 in alleviating AAD in mice, providing valuable insights for understanding and potentially treating antibiotic-related gut issues.
- 15 May 2025
- Published by Springer Nature in Food Science and Biotechnology
- Vol. 34 (11) , 2625-2634
The role of Bifidobacterium animalis QC08 in antibiotic-associated diarrhea in mice
Excessive antibiotic use can lead to gut microbiota dysbiosis, resulting in diarrhea. This study aimed to investigate the effects of Bifidobacterium animalis QC08 (QC08) on the antibiotic-induced diarrhea mouse model using lincomycin hydrochloride. Mice were divided into five groups: normal, diarrhea, a drug group, high-dose QC08 (QC08-H), low-dose QC08 (QC08-L). Compared with the diarrhea group, the QC08-H and QC08-L groups showed a decrease in serum serotonin, interleukin (IL)-17A, IL-6, and malondialdehyde levels, whereas total antioxidant capacity levels increased. In the colon and small intestine tissues of QC08-H and QC08-L treated mice, mRNA expression of cystic fibrosis transmembrane conductance regulator (CFTR), epidermal growth factor receptor (EGFR), and transforming growth factor β1 (TGFβ1) was significantly downregulated, whereas expression of sodium-hydrogen exchanger 1 (NHE1) and NHE4 was upregulated compared to the AAD model group. Altogether, this in vivo study demonstrates the potential of QC08 in alleviating AAD in mice, providing valuable insights for understanding and potentially treating antibiotic-related gut issues.
- Open Access
- 13 November 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (11) , 2307
Therapeutic Effect of Lactiplantibacillus plantarun HFY11 Isolated from Naturally Fermented Yak Yogurt on Lincomycin Hydrochloride–Induced Diarrhea in Mice
This study aimed to observe the therapeutic effect of Lactiplantibacillus plantarun HFY11 (LP-HFY11) on lincomycin hydrochloride-induced diarrhea in mice. The results showed that LP-HFY11 alleviated weight loss and intestinal and colon tissue lesions caused by diarrhea. The serum assay showed that LP-HFY11 decreased interleukin 17A (IL-17A), IL-6, 5-hydroxytryptamine, and malondialdehyde levels and increased total antioxidant capacity in mice with diarrhea. LP-HFY11 also downregulated the mRNA expression of cystic fibrosis transmembrane conductance regulator (CFTR), epidermal growth factor receptor (EGFR), and transforming growth factor beta 1 (TGFβ1) and upregulated the expression of recombinant sodium/hydrogen exchanger 1 (NHE1) and NHE4 in the colon tissues of mice with diarrhea. In conclusion, the study showed that LP-HFY11 could effectively inhibit diarrhea, and the effect was better than that of the drug Bifidobacterium tetragenous viable bacteria tablets (Bifidobacterium-TVBT).
- 13 November 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (11) , 2307
Open AccessTherapeutic Effect of Lactiplantibacillus plantarun HFY11 Isolated from Naturally Fermented Yak Yogurt on Lincomycin Hydrochloride–Induced Diarrhea in Mice
This study aimed to observe the therapeutic effect of Lactiplantibacillus plantarun HFY11 (LP-HFY11) on lincomycin hydrochloride-induced diarrhea in mice. The results showed that LP-HFY11 alleviated weight loss and intestinal and colon tissue lesions caused by diarrhea. The serum assay showed that LP-HFY11 decreased interleukin 17A (IL-17A), IL-6, 5-hydroxytryptamine, and malondialdehyde levels and increased total antioxidant capacity in mice with diarrhea. LP-HFY11 also downregulated the mRNA expression of cystic fibrosis transmembrane conductance regulator (CFTR), epidermal growth factor receptor (EGFR), and transforming growth factor beta 1 (TGFβ1) and upregulated the expression of recombinant sodium/hydrogen exchanger 1 (NHE1) and NHE4 in the colon tissues of mice with diarrhea. In conclusion, the study showed that LP-HFY11 could effectively inhibit diarrhea, and the effect was better than that of the drug Bifidobacterium tetragenous viable bacteria tablets (Bifidobacterium-TVBT).
- Open Access
Effect of Lactiplantibacillus plantatum HFY11 on Colitis in Mice
This study aimed to examine the potential impact of the intervention of Lactiplantibacillus plantatum HFY11 (LP-HFY11) on colitis using in vivo animal trials. The impact of LP-HFY11 intervention on colitis was determined by measuring the levels of relevant indicators in the intestine, colon, and blood after oxazolone-induced colitis in BALB/c mice. The results of the trial show that LP-HFY11 improved the colon weight-to-length ratio, reduced the colitis-induced colon length shortening, and reduced colonic abstinence. Furthermore, it decreased the levels of myeloperoxidase, nitric oxide, and malondialdehyde activities while increasing the glutathione content in the colon tissue of colitis-affected animals. LP-HFY11 lowered the interleukin-10 (IL-10) level and increased the IL-2 level in the serum of colitis mice. LP-HFY11 also upregulated the expression of neuronal nitric oxide synthase, endothelial nitric oxide synthase, c-Kit, and stem cell factor (SCF), and downregulated the expression of IL-8, C-X-C chemokine receptor type 2 (CXCR2), and inducible nitric oxide synthase (iNOS) in the colon tissue of mice with colitis. LP-HFY11 decreased the expression of Firmicutes in the gut while increasing the expression of Bacteroidetes, Bifidobacteria, and Lactobacillus. This indicates that LP-HFY11 could control physiological alterations in the serum and colon tissue, as well as the expression of gut microorganism.
Open AccessEffect of Lactiplantibacillus plantatum HFY11 on Colitis in Mice
This study aimed to examine the potential impact of the intervention of Lactiplantibacillus plantatum HFY11 (LP-HFY11) on colitis using in vivo animal trials. The impact of LP-HFY11 intervention on colitis was determined by measuring the levels of relevant indicators in the intestine, colon, and blood after oxazolone-induced colitis in BALB/c mice. The results of the trial show that LP-HFY11 improved the colon weight-to-length ratio, reduced the colitis-induced colon length shortening, and reduced colonic abstinence. Furthermore, it decreased the levels of myeloperoxidase, nitric oxide, and malondialdehyde activities while increasing the glutathione content in the colon tissue of colitis-affected animals. LP-HFY11 lowered the interleukin-10 (IL-10) level and increased the IL-2 level in the serum of colitis mice. LP-HFY11 also upregulated the expression of neuronal nitric oxide synthase, endothelial nitric oxide synthase, c-Kit, and stem cell factor (SCF), and downregulated the expression of IL-8, C-X-C chemokine receptor type 2 (CXCR2), and inducible nitric oxide synthase (iNOS) in the colon tissue of mice with colitis. LP-HFY11 decreased the expression of Firmicutes in the gut while increasing the expression of Bacteroidetes, Bifidobacteria, and Lactobacillus. This indicates that LP-HFY11 could control physiological alterations in the serum and colon tissue, as well as the expression of gut microorganism.